LIXT logo

Lixte Biotechnology Holdings (LIXT) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

25 October 2007

Indexes:

Not included

Description:

Lixte Biotechnology Holdings is a company focused on developing new cancer treatments. They create innovative drugs that target cancer cells while minimizing harm to healthy cells. Their research aims to improve cancer therapy and provide better options for patients facing this disease.

Events Calendar

Earnings

Next earnings date:

May 09, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

N/A
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

June 05, 2023

Analyst ratings

Recent major analysts updates

No data about analysts updates

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

LIXTE Receives U.S. Patent Issue Notification for Immune Oncology
LIXTE Receives U.S. Patent Issue Notification for Immune Oncology
LIXTE Receives U.S. Patent Issue Notification for Immune Oncology
LIXT
globenewswire.com04 September 2024

Patent Covers Combining LIXTE's LB-100 with Various Innovative Cancer Immunotherapies PASADENA, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc.

LIXTE Biotechnology Provides Update On Recent Activities and Developments
LIXTE Biotechnology Provides Update On Recent Activities and Developments
LIXTE Biotechnology Provides Update On Recent Activities and Developments
LIXT
globenewswire.com19 August 2024

-Collaboration with NKI and Funding Support for New Colorectal Cancer Clinical Trial  by Major Pharma Company-

LIXTE Biotechnology Holdings to Present at Two Investor Conferences
LIXTE Biotechnology Holdings to Present at Two Investor Conferences
LIXTE Biotechnology Holdings to Present at Two Investor Conferences
LIXT
globenewswire.com15 August 2024

-Company to Present August 20 at Investor Summit Summer 2024 Virtual Conference; and September 9-11 at H.C. Wainwright 26 th Annual Global Investment Conference-

Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event
Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event
Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event
LIXT
accesswire.com14 August 2024

NEW YORK, NY / ACCESSWIRE / August 14, 2024 / Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation.

LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial
LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial
LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial
LIXT
globenewswire.com14 June 2024

Clinical trial to test recent findings that show LIXTE's lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system

Scientific Journal Reports Findings that Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System
Scientific Journal Reports Findings that Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System
Scientific Journal Reports Findings that Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System
LIXT
globenewswire.com06 June 2024

LB-100 Generates Neo-Antigens in Cancer Cells that are Presented to the Immune System by Disrupting the Process of RNA Splicing

LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer
LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer
LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer
LIXT
globenewswire.com03 June 2024

PASADENA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today announced the appointment of Jan Schellens, M.D., Ph.D., as Chief Medical Officer (CMO).

FAQ

  • What is the primary business of Lixte Biotechnology Holdings?
  • What is the ticker symbol for Lixte Biotechnology Holdings?
  • Does Lixte Biotechnology Holdings pay dividends?
  • What sector is Lixte Biotechnology Holdings in?
  • What industry is Lixte Biotechnology Holdings in?
  • What country is Lixte Biotechnology Holdings based in?
  • When did Lixte Biotechnology Holdings go public?
  • Is Lixte Biotechnology Holdings in the S&P 500?
  • Is Lixte Biotechnology Holdings in the NASDAQ 100?
  • Is Lixte Biotechnology Holdings in the Dow Jones?
  • When was Lixte Biotechnology Holdings's last earnings report?
  • When does Lixte Biotechnology Holdings report earnings?

What is the primary business of Lixte Biotechnology Holdings?

Lixte Biotechnology Holdings is a company focused on developing new cancer treatments. They create innovative drugs that target cancer cells while minimizing harm to healthy cells. Their research aims to improve cancer therapy and provide better options for patients facing this disease.

What is the ticker symbol for Lixte Biotechnology Holdings?

The ticker symbol for Lixte Biotechnology Holdings is NASDAQ:LIXT

Does Lixte Biotechnology Holdings pay dividends?

No, Lixte Biotechnology Holdings does not pay dividends

What sector is Lixte Biotechnology Holdings in?

Lixte Biotechnology Holdings is in the Healthcare sector

What industry is Lixte Biotechnology Holdings in?

Lixte Biotechnology Holdings is in the Biotechnology industry

What country is Lixte Biotechnology Holdings based in?

Lixte Biotechnology Holdings is headquartered in United States

When did Lixte Biotechnology Holdings go public?

Lixte Biotechnology Holdings's initial public offering (IPO) was on 25 October 2007

Is Lixte Biotechnology Holdings in the S&P 500?

No, Lixte Biotechnology Holdings is not included in the S&P 500 index

Is Lixte Biotechnology Holdings in the NASDAQ 100?

No, Lixte Biotechnology Holdings is not included in the NASDAQ 100 index

Is Lixte Biotechnology Holdings in the Dow Jones?

No, Lixte Biotechnology Holdings is not included in the Dow Jones index

When was Lixte Biotechnology Holdings's last earnings report?

Lixte Biotechnology Holdings's most recent earnings report was on 12 November 2024

When does Lixte Biotechnology Holdings report earnings?

The next expected earnings date for Lixte Biotechnology Holdings is 9 May 2025